Citadel Advisors
ELDN icon

Citadel Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Citadel Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-152,460
Closed -$446K – 13061
2025
Q2 		$413K Buy
152,460
+58,463
+62% +$175K ﹤0.01% 9077
2025
Q1 		$319K Sell
93,997
-95,873
-50% -$395K ﹤0.01% 9440
2024
Q4 		$782K Buy
+189,870
New +$749K ﹤0.01% 7553
2024
Q2 		– Sell
-15,982
Closed -$32.9K – 14513
2024
Q1 		$32.9K Sell
15,982
-7,226
-31% -$12.9K ﹤0.01% 12606
2023
Q4 		$41.8K Buy
+23,208
New +$32.3K ﹤0.01% 11974
2023
Q3 		– Sell
-7,740
Closed -$10.6K – 14490
2023
Q2 		$10.6K Sell
7,740
-23,070
-75% -$48.1K ﹤0.01% 13195
2023
Q1 		$72.7K Buy
+30,810
New +$82.6K ﹤0.01% 11681
2022
Q1 		– Sell
-10,174
Closed -$39.4K – 13810
2021
Q4 		$45K Buy
+10,174
New +$51.5K ﹤0.01% 13304
2021
Q2 		– Sell
-25,062
Closed -$268K – 13830
2021
Q1 		$268K Buy
+25,062
New +$378K ﹤0.01% 11101
2020
Q3 		– Sell
-3,016
Closed -$25K – 10199
2020
Q2 		$25K Buy
+3,016
New +$34K ﹤0.01% 9502
2019
Q4 		– Sell
-3,365
Closed -$38K – 9252
2019
Q3 		$38K Buy
3,365
+1,162
+53% +$16.7K ﹤0.01% 8783
2019
Q2 		$40K Buy
+2,203
New +$96.4K ﹤0.01% 8798

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors's ELDN Position: Q3 2025 in Review

Citadel Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 152,460 shares — an estimated $446K sold.

Citadel Advisors first reported a position in ELDN in Q2 2019 and held it in 12 quarters. The position peaked at $782K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Citadel Advisors reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 152,460 Eledon Pharmaceuticals shares in Q3 2025, an estimated $446K.
  • Citadel Advisors first reported a position in Eledon Pharmaceuticals in Q2 2019 and held it in 12 quarters.
  • Citadel Advisors's Eledon Pharmaceuticals position peaked at $782K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.